Venadaparib

Venadaparib (IDX-1197) is a potent, selective and orally active PARP inhibitor with IC50s of 1.4 nM and 1.0 nM for PARP1 and PARP2, respectively. Venadaparib does not sensitive to PARP-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research[1][2].

Product Specifications

CAS Number

[1681017-83-3]

Product Name Alternative

IDX-1197

UNSPSC

12352005

Target

PARP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/venadaparib.html

Purity

98.11

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NN=C(CC2=CC=C(F)C(C(N3CC(CNC4CC4)C3)=O)=C2)C5=C1C=CC=C5

Molecular Formula

C23H23FN4O2

Molecular Weight

406.45

References & Citations

[1]Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107.|[2]Myongjae Lee, et al. Abstract A106: Development of IDX-1197, a novel, selective, and highly potent PARP inhibitor. American Association for Cancer Research, 2018.